Conditions: Diabetic Nephropathies
Keywords: Diabetic nephropathy chronic kidney disease PF-00489791 phosphodiesterase PDE5
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 256
Healthy volunteers: no

Brief summary:
PF-00489791 is an inhibitor of phosphodiesterase type 5. Our hypothesis is that PF-00489791 will enhance the relaxation of blood vessels within the kidney and so reduce blood pressure, improving renal function.

Detailed description:

Arms:
arm 1: None arm 2: None

Interventions: intervention 1: PF-00489791 intervention 2: Placebo
Intervention descriptions: intervention 1: Tablet, 20 mg once daily for 12 weeks intervention 2: Tablet, placebo once daily for 12 weeks

Protocol document: